BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24771047)

  • 1. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.
    Aleskandarany MA; Negm OH; Green AR; Ahmed MA; Nolan CC; Tighe PJ; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):339-48. PubMed ID: 24771047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
    Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
    Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype.
    Jeong H; Ryu YJ; An J; Lee Y; Kim A
    Histopathology; 2012 May; 60(6B):E87-95. PubMed ID: 22439911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
    Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas.
    McCart Reed AE; Kutasovic JR; Vargas AC; Jayanthan J; Al-Murrani A; Reid LE; Chambers R; Da Silva L; Melville L; Evans E; Porter A; Papadimos D; Thompson EW; Lakhani SR; Simpson PT
    J Pathol; 2016 Mar; 238(4):489-94. PubMed ID: 26510554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
    Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of epithelial-mesenchymal transition markers at the invasive front of oral squamous cell carcinoma.
    Costa LC; Leite CF; Cardoso SV; Loyola AM; Faria PR; Souza PE; Horta MC
    J Appl Oral Sci; 2015; 23(2):169-78. PubMed ID: 26018309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of reverse phase protein array for molecular classification of breast cancer.
    Negm OH; Muftah AA; Aleskandarany MA; Hamed MR; Ahmad DA; Nolan CC; Diez-Rodriguez M; Tighe PJ; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2016 Jan; 155(1):25-35. PubMed ID: 26661092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial mesenchymal transition in urothelial carcinoma: twist in the tale.
    Paliwal P; Arora D; Mishra AK
    Indian J Pathol Microbiol; 2012; 55(4):443-9. PubMed ID: 23455777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.
    Prins MJ; Ruurda JP; Lolkema MP; Sitarz R; Ten Kate FJ; van Hillegersberg R
    J Clin Pathol; 2015 Jul; 68(7):529-35. PubMed ID: 25855799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis.
    Liu JB; Feng CY; Deng M; Ge DF; Liu DC; Mi JQ; Feng XS
    World J Surg Oncol; 2017 Aug; 15(1):139. PubMed ID: 28764784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of e-cadherin in primary breast cancer and corresponding lymph node metastases.
    Fulga V; Rudico L; Balica AR; Cimpean AM; Saptefrati L; Margan MM; Raica M
    Anticancer Res; 2015 Feb; 35(2):759-65. PubMed ID: 25667455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
    Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
    Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
    Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
    Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
    J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
    Abd El-Rehim DM; Ball G; Pinder SE; Rakha E; Paish C; Robertson JF; Macmillan D; Blamey RW; Ellis IO
    Int J Cancer; 2005 Sep; 116(3):340-50. PubMed ID: 15818618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.